Buy
|
Original-Research: Cantourage Group SE - from NuWays AG
Classification of NuWays AG to Cantourage Group SE
Q1 on track to hit a new record Following the record Q4 with € 21m sales, Cantourage should be on track to hit another record high quarter with Q1. During the first two months of the year, the company generated € 14.9m sales, already more than 2x last year’s whole Q1 with € 6.2m (regulatory change not until April of last year). Assuming no supply chain disruptions, Cantourage is seen to reach some € 22m sales in Q1 (eNuW). This bodes well with our 2025 estimates, which imply 67% yoy sales growth to € 86m (so far no FY25 guidance). While we have factored in some weaker months during the summer and a margin of safety, Cantourage currently looks set to be on track to beat our estimates, especially when assuming positive contributions from an increased supplier depth and successful de-bottlenecking efforts at processing sites. With its top-line further improving, scale effects should begin to kick in. Despite ongoing expansion expenses, the group’s EBITDA margin is seen to grow to 10% (eNuW). Further capacity expansion announced. To be able to cope with the surging demand across its three core markets, Germany, the UK and Poland, as well as geographical expansion, Cantourage decided to further expand its processing capacity. This comes less than 10 months after the last increase to 14t p.a. (€ 100m at € 7.5 per gram), underpinning the unbroken demand and sales potential way beyond € 100m, in our view. While the company has not announced any detail, we would expect the additional capacities to mainly come from third-party processing plants, keeping the business capital light. Threats from political uncertainties limited. German elections turned out as expected with Christian Democratic Union (CDU) and Social Democratic Party (SPD) forming the new government. While CDU has historically opposed a broader cannabis legalization, SPD was a driving force behind the changes implemented almost one year ago. While we see the potential of re-regulation on the recreational side, i.e. cannabis clubs and growing own plants, a full return to the “old” model seems unlikely as it would come with a high degree of complexity as well as a wave of lawsuits. Importantly, Cantourage is only active in the medical space, we hence regard the risks to its business model as limited. Further, as the company has been increasing its operational footprint outside of its home turf, potential implications from any regulatory change are rather decreasing going forward. BUY with an unchanged € 12.50 PT based on DCF. You can download the research here: http://www.more-ir.de/d/31946.pdf For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2098458 11.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.